ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0001146.1|Cyclothiazomycin_3 # 3625 # 3807 # 1 # ID=1_3;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.656	BGC0001146.1|Cyclothiazomycin_3 	3625	3807	+	Loose	750	23.483	tet(52)	30.3	3004587	protein homolog model	n/a	n/a	tetracycline antibiotic	antibiotic inactivation	tetracycline inactivation enzyme	ATGGACGCGAACCTGGTGCTGGACCTCGACGACCTGAGCGTGGACCAGCTCGACATTCTCCCGACCGCCCCCGGCTCCACCCTGGAGTCGATCAACGTCGGCCACGCCATGGTCGAGATCGGCGCTTCGAACTGCACCTCGAAGGGCTCGCCCGCGAGCTGCTGCTCTTGTTGCTGCTGCTGA	MDANLVLDLDDLSVDQLDILPTAPGSTLESINVGHAMVEIGASNCTSKGSPASCCSCCCC	MSNVNKILVIGAGIAGPAACYWLRRFGFSPVLVERSASLRKGGHALDVRGVAIDLVKRMGIYQKIYNMRTQLEFGRHVDPEGNTLHEEKGERFGFREGQDVEIIRSDLVEILIDSIEGVPLQFNQTIESVKQTDAVVEVQFKDGRTEHFDLVIGADGLHSTTRRIVFDKHEYKLNDLGAYFSVFSIPNYLNLNNTEVQCEANQKLLSITSDKNRKMAEVAFSFRGQNVLNNVRDESEQRRVLRDTFQDFGWEAPRILELMSDSDDFYSDSFTQVIMKSWTKGRVALLGDAAYSASPISGQGNNLALVGAYVLAGELKQAGGNYKRAFDRYNEILRPFIEANQKLGVLVNESFLVRDEVSKEVAEERSNNIMEQVKIASNMIVLQDYANPH	15.38	gnl|BL_ORD_ID|2698|hsp_num:0	3289			318	417	tetracycline; oxytetracycline
BGC0001146.1|Cyclothiazomycin_4 # 3901 # 5853 # 1 # ID=1_4;partial=00;start_type=ATG;rbs_motif=GGA/GAG/AGG;rbs_spacer=5-10bp;gc_cont=0.750	BGC0001146.1|Cyclothiazomycin_4 	3901	5853	+	Loose	600	27.335	vanJ	35.71	3002914	protein homolog model	n/a	n/a	glycopeptide antibiotic	antibiotic target alteration	vanJ membrane protein	ATGCAGCAGGGGAACGTGGCGGACCGGCCGGCCGGACTCGCGGTACGGGGCGACGGGCTGCTCGCCCAGGCGGTCCGCGCGGCGGTCTCCCGCCGGCACCCGTCGGCCGCCGAGGACAGCGACCGGTGCGCCGCACTGCTCACCGTGGACGACGGCTGGCAGGACGCCGACCGGACGAGCCGGCCGGATCTGCCGTGGCTGCCCGTCCGGGTGGAGCTGGGCAATGTCGTCATCGGGCCGCTCGAACTGCCGGGCCGGCCGGGATGCGCGCAGTGCGCCCGTACCCGCAGGCAGCGGGCCCTGGGACAGGACAGCCCCCGCGCCGAACTGCTGCGCCGGCACGGCGACCGGCTCGCCGAACGGCCGTCCCCGCTGCTGTCCGCCTGGGCGCGCGACACCGTCGCGGCCTTCGTGGAGGCGGAAGCCGCCGCCGTGCTCGACGACCCGGAGCGCGCCGGCACCCGCAACGCGATCACCATCATCGGTCTGGCCGGCCTCACCGCCGACTCCCACCCGTTCCTGCCCGACCCCTGCTGCCCCCGCTGCGGCAGCCTCCCCGACGACGGGCCGCCGATCCTGATGGACACCCCGCAGCCCAAGCTCGACCGGGACACCTACCGCGTCCGCAGCCTCGACACCGGCTGGGACGGTCTGCTGCGGACGTACGTGGACGGACACACCGGCATCGTCCAGCAGCTCGACGTACGGACCGACTACGCCTACCCCATGGTCTCCGCGCCGCTGCGGCTGCCCGACGGCATCCAGGAGGCGGGCTTCGGCCGCGGCCTGGACTACACCGGGTGCGAACGCACCGCGCTGGCCGAGGCGCTGGAGCGGCTGGGCGGCGCCCGGCCCGGCGGCCGGCGCACGGCCGTCCGCGCGGGCTACGAGCAGGTCGCCGACCGCGCGGTCCGCCCCACCGACCTGGGCCTGTACCCGCCGGACCGGTACGCCGACCCGGAATTCCCCTATCCGGCGTTCACCCCCGACCTGGAGATCAACTGGGTGTGGGGGCACTCCTTCGGCCGCGGCGGCCCCGTGCTGGTACCCGAGGACTACGCCTACTACCGCACCCGGCACGGGAACGACACGGCCCGCCCGCTGGCGTACGAGGTCTCCAACGGCTGCGCCCTCGGCGGCTGTCTGGAGGAGGCCGCGCTGCACGGCATCCTGGAGCTTGCCGAGCGGGACGCCTTCCTGCTGACCTGGTACGCCCGGCTGCCGGTGCCGCGCGTGGACCTGGACACCGTGGCCGACCCGGCGGTCCGGCTGCTGGTGGAGCGCATCCGGCAGGACACCGGGCACCGGGTCGCCGCGTTCGCCACCACGCCCGAGCACGGCATCGCCACGTCCTGGGTGATGGCCGTCCACCCCGGGGACGCGGTGGAGCCCGCCGCGATCTGTGCCGCGGGCGCCCACTTCGATCCCGAGAAGGCGCTGCTCAACGGCCTGTTGGAGCTGACAGCGAACCTGGGCTGGAACCGCGCCGCCTACCGCGAGGAACTGCGCCGGATCGAGGGCATGGTCGCCGACCCGCACCAGGTGCGGGAGATGCGCGACCACGCGCTGCTGTACTGCCATCCGGACGCCTACGACCGGTTCGCCTTCCTGCCCGGCGAGGAGACGGCCCGGCCGGTGGCCGAGGCGTTCGCCCGCGCCACCTGCCGGCCGCGCCACGCGGACCTGCGCGACGACCTCGCCGAGGTGGTCGAGCGCTTCACCGCCCGCGGCCTGGACGTGATCGTGGTCGACCAGACCACCGACGAGCACCGCGCCGCCGGCTTCGCCTGCGCGAAGGTGATCATCCCCGGACTGCTGCCGATGACCTTCGGGCACCGGATGAGCCGTACCCACGGCCTGCCCCGGCTGTACGACCTGCCGGCCCGGCTCGGGTACCGGGACGGGCCGCTGGAGCCGGCCGACGTCAACCCGCATCCGCACCCGTTCCCGTGA	MQQGNVADRPAGLAVRGDGLLAQAVRAAVSRRHPSAAEDSDRCAALLTVDDGWQDADRTSRPDLPWLPVRVELGNVVIGPLELPGRPGCAQCARTRRQRALGQDSPRAELLRRHGDRLAERPSPLLSAWARDTVAAFVEAEAAAVLDDPERAGTRNAITIIGLAGLTADSHPFLPDPCCPRCGSLPDDGPPILMDTPQPKLDRDTYRVRSLDTGWDGLLRTYVDGHTGIVQQLDVRTDYAYPMVSAPLRLPDGIQEAGFGRGLDYTGCERTALAEALERLGGARPGGRRTAVRAGYEQVADRAVRPTDLGLYPPDRYADPEFPYPAFTPDLEINWVWGHSFGRGGPVLVPEDYAYYRTRHGNDTARPLAYEVSNGCALGGCLEEAALHGILELAERDAFLLTWYARLPVPRVDLDTVADPAVRLLVERIRQDTGHRVAAFATTPEHGIATSWVMAVHPGDAVEPAAICAAGAHFDPEKALLNGLLELTANLGWNRAAYREELRRIEGMVADPHQVREMRDHALLYCHPDAYDRFAFLPGEETARPVAEAFARATCRPRHADLRDDLAEVVERFTARGLDVIVVDQTTDEHRAAGFACAKVIIPGLLPMTFGHRMSRTHGLPRLYDLPARLGYRDGPLEPADVNPHPHPFP	MVLRSAARPELWKRAPVLTVSALLLGLVMMLHAEIPNRFGSVGSLVETFLPWFGLFVPVLAAGALWRRSAAAVTALVLPVTVWLSLFGGLLGDKSGAGGEFTMASHNVGAENPDPAGTARDLAASGVDVLALEEITAQDREVYEKGLAREYPYHTVQGTVGLWSKLPLSGTRPVDIATDYGPLADTKPADVTMAGNRALRTTVATERGPLVVYVAHLGSVRLNPRAGFWTDSRDRNAWALGEALAADRSERIALLGDLNGTVDDRALAGITSQLHSVQEAAGNGFGFTWPAKFPVARIDQILVRGVEPTGSWTLPATGSDHLPVAAGVSW	196.97	gnl|BL_ORD_ID|2036|hsp_num:0	2240			771	897	teicoplanin
BGC0001146.1|Cyclothiazomycin_5 # 5939 # 8533 # 1 # ID=1_5;partial=00;start_type=ATG;rbs_motif=GGA/GAG/AGG;rbs_spacer=5-10bp;gc_cont=0.748	BGC0001146.1|Cyclothiazomycin_5 	5939	8533	+	Loose	700	26.9498	cmx	32.14	3002703	protein homolog model	n/a	n/a	phenicol antibiotic	antibiotic efflux	major facilitator superfamily (MFS) antibiotic efflux pump	ATGAGTGGCTTCCACGTCGCGGACACGTTCGGCGTACGCATCGGTGGTCTGCCGGTGTCGGTGCTGGACGGTTTGCGGTCGGACGAGGTGTGGCGGCGGACCGGCGCGCTGCTCGACGGCGCGCGGGAACTGGCCGACCGGGGCGCGGAACTCTCCGACGCGCTCTACGCGTTGATCGGGCAGGAGACCGGCGTCAAGGCGGCGCTGGTCGCGCTGCGCCGGGCGGTGCACAACCAGCGGACGCCGGGCGAGCGCTGCTGGAACGACGAGGTGCGCGCCGCCCTGCCCGCCGAAGTGGTGGCGGACGTCGAGCGGTGGGCGGAGCTGCTGGCGGCCCACCGGGCCGGCACCGCAGCCCTGGACGGCCTGCTCCCGCAGGACGCGGCCGACCGCCGCGCCGCCCTGCGCGAGGCGGCCGCCCAACCGGTGTTCCGGCACGGCCTGATCCAGGGCAGCCCTGTCCTCCACGAGCAGTTGCGCAAGTGGCTGGCGCGTCCCGAAGGCGCCGTGCCGGACCGCAAGCTGGCGCTCCGGCTGGCCAAGTACCTCGCCCGGGTGGCCGCCAAGACCAGCCCGTTCAGCACCTTCACCGTCAGCGGCCTCGGCCGGTGGGACGGTCCGCGCCCGGACGGGGACGGACCGGCGGTGCGCGACACCGTCGAGATCAACCTGTGGCTCGTCCAGCAACTTGTCCGGCGGCTGCGCGAGCACCCGGCCCTGGCGCCCGCCGTCCGGCTGCGGGTCAACCCGAGCGCCCACCAGGCCGACGGGCACTGGGAGTTCCTGGGCCCCGGCGAGGAGGAGCCGCTACGCACCCTGCCGGTGTCCCCGCCGGTCCAGGCCTGCGTGGACTTCCTCGCCGACGGTGCCCGCCCGCGCCACGAGGTGGCCGCCCACCTGACCGAGCGGAGCGGTGCCTCCCCGGAGCAGGCCGAGCGCTATGTCGCGCGGCTCACCGAACTCGGTGTGCTGGAGACCGTGCCCCCCTTCTCCGAGCAGGCGATGGACCCGCTCGCCGAACTGCGGGCCTGGGTGGACACCGGCGGCCCGGAGCTGACCGAGGTGTCGGCGCGGCTCAAGGAGGTGGCCGCGCTGCTGGACGGGTACCCGGAGCTGACCGACCCGGACGCCCGCCGGCGGCGCACCGAGGAGATCCACCGGGCGCTGGGCCGGGTCGCCGACCTCGTCGGCCCGGAGCAGGTCATCGTGCCGCCCAAGAACTACATCATCGAGAACGCCCTGCTCGTCGGGCCGCCGCCGGCCCAGGACCGGACGGCGTGGGAACCGGTGCTGCGCGACCTGGACACCGTCCGCCGCTGCTACGCGGCGCTCGACCCGGCGCTGCCCGGACGGGTGGCGCTGGCCCGGCTGTTCACCACGCGCTTCGGGAGCGGCGCGAGCGTGCCGTTCCTCGCGTTCCACCGTGCCGTCCAGGAAGAGATGCGTACGGACCCGCAGCTGCCCGGCCTGCTGTCCGTCTCGCAGCACGGCTACGCGCCGCTCGCCGACAGCCCGCTGCCCCGGATCAAGGAGCTGCTGCGGGTACGGGCCGGGCTCACCGGCGCGGCCCTGAACGCACGGCCGGACGCCGACGGGGTGGTGCACGTCGACCCCGCGCGGCTGGCCGCGCTGGCCGACAGCTGGCCCGCGTGGATGCGGCCGCCCGGCTCGGTCGCGTTCTACGGCCAGCTGACCGGCGGGTCCGAGGACCCGGCCGGGTTCGTGGTCAACGCCGTCAACGCGGGGCACGGGCGGGGCCGCGACCGCATCCGGCGGCTGCTCGGCCAGGCCGGCGTCACCGTGGCGGGCGAACCGTCCGGCCCGCCCGGCGACGTCATCCTGGCGGACACCTGCCGCCATTACGGCAGCAACGTGGGCCTGCGCGACCTGACCATGACCGACGAACTCGACTACCCCGGCTCGGCGAGCCCGCGCCCGGCGGAGCGGCGCATTCCGCTGCGCGACCTGGAGGTGCGCCACGACCCGGCGCTGGACCTCCTCGTGCTGTGGTCGCGCACCCGCGACCGCGAGGTGCGGCCGGTGCACCCCAGCCTGATCGCGGAGTTCTGGCTGCCGCCGGCGATGCGGCTGCTGGTCCAGGCGTTCGGCGACACGCCGACGCTGCTGATCCCCGGCCGGCGGATGTTCGGCGACATCTCCCCCGCCACGGCACAGGGCCTGCTGCACGAGCCCAGGATCACGATCGGCACGGTCACCGTCAGCCGCCGCCAGTGGGTGTTCCGCACCGACGAGGCGCCGGTACGCGCCAAGGGCGAGGCGGACCGCCCGTACCTGCTGCGGCTGGCCGCCTGGCTGCGCGAACACGGCATCCCCGAGCGCTGCTTCGTGCGCGCGCTGGACCCGTCCATGCTGACCGACGGCAACGTCTGGCAGCTCAAGTCCCGCAAGCCGCTGTACATCGACTTCGCGAACCTGCTCCTGACCGGACTGTTCGAGCGCATGCTCGCCGAGCGGGGCAACCTGCTGTTCCTCCAGGAAGCCCTGCCCGACCCGTCCGCCGCGCCGCACTACGGCGACGCCGGAGCCCGCGTCACCGAACACCTCGTGGAGGTCGGTCACCATGGCCGCTGCTGA	MSGFHVADTFGVRIGGLPVSVLDGLRSDEVWRRTGALLDGARELADRGAELSDALYALIGQETGVKAALVALRRAVHNQRTPGERCWNDEVRAALPAEVVADVERWAELLAAHRAGTAALDGLLPQDAADRRAALREAAAQPVFRHGLIQGSPVLHEQLRKWLARPEGAVPDRKLALRLAKYLARVAAKTSPFSTFTVSGLGRWDGPRPDGDGPAVRDTVEINLWLVQQLVRRLREHPALAPAVRLRVNPSAHQADGHWEFLGPGEEEPLRTLPVSPPVQACVDFLADGARPRHEVAAHLTERSGASPEQAERYVARLTELGVLETVPPFSEQAMDPLAELRAWVDTGGPELTEVSARLKEVAALLDGYPELTDPDARRRRTEEIHRALGRVADLVGPEQVIVPPKNYIIENALLVGPPPAQDRTAWEPVLRDLDTVRRCYAALDPALPGRVALARLFTTRFGSGASVPFLAFHRAVQEEMRTDPQLPGLLSVSQHGYAPLADSPLPRIKELLRVRAGLTGAALNARPDADGVVHVDPARLAALADSWPAWMRPPGSVAFYGQLTGGSEDPAGFVVNAVNAGHGRGRDRIRRLLGQAGVTVAGEPSGPPGDVILADTCRHYGSNVGLRDLTMTDELDYPGSASPRPAERRIPLRDLEVRHDPALDLLVLWSRTRDREVRPVHPSLIAEFWLPPAMRLLVQAFGDTPTLLIPGRRMFGDISPATAQGLLHEPRITIGTVTVSRRQWVFRTDEAPVRAKGEADRPYLLRLAAWLREHGIPERCFVRALDPSMLTDGNVWQLKSRKPLYIDFANLLLTGLFERMLAERGNLLFLQEALPDPSAAPHYGDAGARVTEHLVEVGHHGRC	MPFALYMLALAVFVMGTSEFMLAGLLPAIATELDVSVGTAGLLTSAFAVGMVVGAPVMAAFARRWPPRLTLIVCLLVFAGSHVIGAMTPVFSLLLITRVLSALANAGFLAVALSTATTLVPANQKGRALSILLSGTTIATVVGVPAGALLGTALGWRTTFWAIAILCIPAAVGVIRGVTNNVGRSETSATSPRLRVELSQLATPRLILAMALGALINGGTFAAFTFLAPIVTETAGLAEAWVSVALVMFGIGSFLGVTIAGRLSDQRPGLVLAVGGPLLLTGWIVLAVVASHPVALIVLVLVQGFLSFGVGSTLITRVLYAASGAPTMGGSYATAALNIGAAAGPVLGALGLATGLGLLAPVWVASVLTAIALVIMLLTRRALTKTAAEAN	220.97	gnl|BL_ORD_ID|1252|hsp_num:0	1366			27	195	chloramphenicol
BGC0001146.1|Cyclothiazomycin_6 # 8520 # 9533 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=GGAGG;rbs_spacer=5-10bp;gc_cont=0.739	BGC0001146.1|Cyclothiazomycin_6 	8520	9533	+	Loose	475	26.1794	cph	28.7	3007075	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic inactivation	capreomycin phosphotransferase	ATGGCCGCTGCTGACCGCCCCCTGGACCCCGCCACCGCCGGTGCGTCCGACTGGGTGTGCGCCCACGTCTTCCAGGACACCGGCCACGACGCCCTGCTCACCGGCTGTCTGCGGCCGCTGGCCAAGGAGCTGACCGCCGACGGGCTGCTGCACCGGTACTTCTTCCTGCGGTACTGGGAAGGCGGTCCGCACGTACGGATGCGCTTCCTGCCCACCGGTACGGCGGCCTCCCGCGAGGTACGGCAGCGGGTGGTCACGGCGGTCGGCGCGTTCCTGCGGGACCACCCGGCCCCTGACACGGTGGACCGCACGCGGTACGCCGGGCTGGCCGGCGAACTGGCCGCCCTGGAGGACCTCTCCGAGCACGACCGGGAACTGCGGCCCAACAACACGGTCGAGTTCCTGCCGTACCTGCGCGAGCACGCGGTGTACGGGCACGGTCCGGCCATGGCCGCGACCGAGCAGCACTTCCACGAGTCCAGCGAACTGGCCCTGGCGCTGATCGCGGCCGGTACGACCGGCCAGCAGCGGGCGGCGATCGCCCTCGACCTGATGCTGGCCGTCCTGGCCCTCTGCGACGAGCTGCGCGCGCAGTGGGTCGACAGCGGACAGCCGCTGGTCCCCTTCGCCGAGGGCTCCGAACCCGCCGCCACCGAGGAGCACTACCTGGCCCGGCGGGAGCACCTGCGGGAACGCGCGCTGCGCGTGTGGCAGCTCGCCCCGGACCCCACCGGGGCGACCCCGCAGGCGCACTGGCTGCGGTCGCTGCGCACACTGCGGGACCGGCTCAGCGGCTGGGAGGACGCCGGCACGTTCACCTCCGAGTGGGCCCGCTCCCCGCTGAACCAGGGCCCGGACCTGGCCGCGCTGCCGCACCCGGCCACCACGCTGATCCTGCTGCGCTGCGCGCACCTGGCGAACAACCGGCTCGGGCTGACCCTGAGCGAGGAGAACCACCTGCGCTTCCTGGCCGGCCGGATCGTCACCGACCTGCCGTCGCTTCCGGTGCGCTGA	MAAADRPLDPATAGASDWVCAHVFQDTGHDALLTGCLRPLAKELTADGLLHRYFFLRYWEGGPHVRMRFLPTGTAASREVRQRVVTAVGAFLRDHPAPDTVDRTRYAGLAGELAALEDLSEHDRELRPNNTVEFLPYLREHAVYGHGPAMAATEQHFHESSELALALIAAGTTGQQRAAIALDLMLAVLALCDELRAQWVDSGQPLVPFAEGSEPAATEEHYLARREHLRERALRVWQLAPDPTGATPQAHWLRSLRTLRDRLSGWEDAGTFTSEWARSPLNQGPDLAALPHPATTLILLRCAHLANNRLGLTLSEENHLRFLAGRIVTDLPSLPVR	MTLSHLVDVVRRAHPDVDLEGAGVHSGQFHDVLIARDRVFRFPKTAGAAAELPGRVAVLTAVDAVELGVGVPVPLSEVRDGGPHGFLVLSRLHGTPLERGDATSPEVIDVVAAEFARVLRAMAGADVEKLRLVLPVADAGRWRGFAGRVRATLFPLMSEDGRARAERELAAAVAMDHVATGLVHGDLGGENVLWQQVEELPRLTGIVDWDEAKVGDPAEDLAAVGASYGPELVERVVALLGAGDLWPRIRAYQGTFALQQALAGAEDGDDEELEDGLTAYR	119.93	gnl|BL_ORD_ID|4772|hsp_num:0	5768			126	453	capreomycin
